595 related articles for article (PubMed ID: 34852736)
1. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
Sousa TR; Rema J; Machado S; Novais F
Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
[TBL] [Abstract][Full Text] [Related]
4. Psychedelics and Psychedelic-Assisted Psychotherapy.
Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
[TBL] [Abstract][Full Text] [Related]
5. Psychedelics for treatment resistant depression: are they game changers?
Kalfas M; Taylor RH; Tsapekos D; Young AH
Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
[TBL] [Abstract][Full Text] [Related]
6. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
[TBL] [Abstract][Full Text] [Related]
7. Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders.
Mertens LJ; Preller KH
Pharmacopsychiatry; 2021 Jul; 54(4):176-190. PubMed ID: 33472250
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis.
Yao Y; Guo D; Lu TS; Liu FL; Huang SH; Diao MQ; Li SX; Zhang XJ; Kosten TR; Shi J; Bao YP; Lu L; Han Y
Psychiatry Res; 2024 May; 335():115886. PubMed ID: 38574699
[TBL] [Abstract][Full Text] [Related]
9. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J
Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346
[No Abstract] [Full Text] [Related]
10. Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.
Goldberg SB; Shechet B; Nicholas CR; Ng CW; Deole G; Chen Z; Raison CL
Psychol Med; 2020 Dec; 50(16):2655-2666. PubMed ID: 33143790
[TBL] [Abstract][Full Text] [Related]
11. Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans.
Madrid-Gambin F; Fabregat-Safont D; Gomez-Gomez A; Olesti E; Mason NL; Ramaekers JG; Pozo OJ
Biomed Pharmacother; 2023 Dec; 169():115775. PubMed ID: 37944438
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular safety of psychedelic medicine: current status and future directions.
Wsół A
Pharmacol Rep; 2023 Dec; 75(6):1362-1380. PubMed ID: 37874530
[TBL] [Abstract][Full Text] [Related]
13. Human behavioral pharmacology of psychedelics.
Strickland JC; Johnson MW
Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
[TBL] [Abstract][Full Text] [Related]
14. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.
Leger RF; Unterwald EM
J Psychopharmacol; 2022 Jan; 36(1):20-30. PubMed ID: 34519567
[TBL] [Abstract][Full Text] [Related]
15. Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies.
Calleja-Conde J; Morales-García JA; Echeverry-Alzate V; Bühler KM; Giné E; López-Moreno JA
Addict Biol; 2022 Nov; 27(6):e13229. PubMed ID: 36301215
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Applications of Classic Hallucinogens.
Bogenschutz MP; Ross S
Curr Top Behav Neurosci; 2018; 36():361-391. PubMed ID: 28512684
[TBL] [Abstract][Full Text] [Related]
17. Drug-drug interactions involving classic psychedelics: A systematic review.
Halman A; Kong G; Sarris J; Perkins D
J Psychopharmacol; 2024 Jan; 38(1):3-18. PubMed ID: 37982394
[TBL] [Abstract][Full Text] [Related]
18. Psychedelics and Personality.
Aixalà M; Dos Santos RG; Hallak JEC; Bouso JC
ACS Chem Neurosci; 2018 Oct; 9(10):2304-2306. PubMed ID: 29863323
[TBL] [Abstract][Full Text] [Related]
19. Default Mode Network Modulation by Psychedelics: A Systematic Review.
Gattuso JJ; Perkins D; Ruffell S; Lawrence AJ; Hoyer D; Jacobson LH; Timmermann C; Castle D; Rossell SL; Downey LA; Pagni BA; Galvão-Coelho NL; Nutt D; Sarris J
Int J Neuropsychopharmacol; 2023 Mar; 26(3):155-188. PubMed ID: 36272145
[TBL] [Abstract][Full Text] [Related]
20. Psychedelic drugs for psychiatric disorders.
da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]